Market Overview

Repros Therapeutics Says FDA Granted End of Phase 2 Meeting in Late May to Discuss Proellex(R)-V Phase 2 Design

Related RPRX
Repros Submits New Drug Application to FDA for Androxal
Morning Market Movers
FDA imposes limits on testosterone drugs and labeling changes to warn of potential heart risks (Seeking Alpha)

Repros Therapeutics Inc.^® (Nasdaq: RPRX) today announced that the FDA has agreed to a Type B meeting scheduled for the last half of May to discuss the Phase 3 development of Proellex® as a vaginally administered product for the treatment of uterine fibroids. During the meeting, Repros will discuss the proposed plans for a Phase 3 study, the FDA's requirements for the size of the safety population and the adequacy of the already completed preclinical studies to support a marketing application.

Once the meeting is held, the Company will report the outcome to the financial community in a timely fashion.

Posted-In: News FDA


Related Articles (RPRX)

Around the Web, We're Loving...